[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"PF-07321332","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"PF-07321332","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Pfizer"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ ICMR","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ ICMR"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Hetero Drugs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Pfizer Inc \/ Hetero labs","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Hetero labs"},{"orgOrder":0,"company":"Nortec Quimica","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nortec Quimica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nortec Quimica \/ The Medicines Patent Pool","highestDevelopmentStatusID":"9","companyTruncated":"Nortec Quimica \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Codexis","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Codexis \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Codexis \/ Pfizer"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zenara pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zenara pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zenara pharma \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Zenara pharma \/ Pfizer"},{"orgOrder":0,"company":"CVS Pharmacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CVS Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CVS Pharmacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CVS Pharmacy \/ Not Applicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ritonavir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"Hetero","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hetero \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero \/ Not Applicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medical \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Yale School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Yale School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Yale School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"CSPC Pharmaceutical Group \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"CSPC Pharmaceutical Group \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"The Medicines Patent Pool \/ Strides Pharma Science","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Strides Pharma Science"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Nirmatrelvir
Details :
Paxzen (nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Details :
With this agreement, the active pharmaceutical ingredient nirmatrelvir can be fully manufactured in Brazil by Nortec, ensuring safety and adherence to treatment for countries such as: South Africa, Tanzania, Venezuela, Bolivia, Ethiopia, Haiti, Honduras,...
Details :
Paxlovid generic version (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 Mpro inhibitor therapy. It is been approved for the treatment of long COVID-19 in adults.
Details :
Paxlovid (Nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Details :
Under the agreement, Pfizer will commercialize Paxlovid (nirmatrelvir with ritonavir), the first oral antiviral pill approved by the U.S. Food and Drug Administration, for the treatment of privately insured commercial patients with prices to be negotiate...
Details :
The partnership aims to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid (nirmatrelvir/ritonavir) in an attempt to improve the access for treatment in China.
Details :
Paxlovid (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of long COVID-19 in adults.
Details :
Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of long COVID-19 in adults.
Details :
Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It is being developed for the treatment of mild-to-moderate COVID-19 in adults.
Details :
Hetero’s ‘NIRMACOM’ (nirmatrelvir), a generic version of Pfizer’s COVID-19 oral antiviral drug ‘PAXLOVID’ is co-packaged with ritonavir tablets. The combi pack, launched by Hetero as NIRMACOM, will contain nirmatrelvir 150 mg (2 tablets) and ...
Reset All
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
